CytomX Therapeutics logo

CytomX TherapeuticsNASDAQ: CTMX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

08 October 2015

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$77.72 M
-83%vs. 3y high
40%vs. sector
-70%vs. 3y high
12%vs. sector
-156%vs. 3y high
8%vs. sector
-92%vs. 3y high
17%vs. sector

Price

after hours | Thu, 31 Oct 2024 22:25:20 GMT
$0.99+$0.00(+0.48%)

Dividend

No data over the past 3 years
$25.11 M$17.51 M
$25.11 M-$6.53 M

Analysts recommendations

Institutional Ownership

CTMX Latest News

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors
globenewswire.com09 September 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that the first patient has been dosed with CX-801 monotherapy in a Phase 1 study (NCT06462794) in patients with solid tumors. CX-801 is a dually-masked interferon alpha-2b PROBODY® cytokine with potential broad applicability in both traditionally immune-oncology sensitive as well as insensitive (cold) tumors.

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
globenewswire.com18 June 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference on Tuesday, June 25, 2024, at 2:00 p.m. ET.

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer
globenewswire.com17 June 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.

Buy Alert: 3 Penny Stocks That Will Explode in 2024
investorplace.com05 June 2024 Sentiment: POSITIVE

When the term penny stocks to buy is thrown around, ideas of high-risk-high-reward, overnight wealth generation and potential scams may come to mind. However, investing in carefully-selected penny stocks can yield a much less volatile experience.

CytomX Therapeutics Announces New Employment Inducement Grants
globenewswire.com16 May 2024 Sentiment: NEGATIVE

On May 15, 2024, CytomX Therapeutics, Inc. (Nasdaq: CTMX) granted two new employees options to buy a total of 130,000 shares of the company's common stock at an exercise price of $1.96 per share, matching the closing price on the date of the grants.

CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
Zacks Investment Research02 May 2024 Sentiment: POSITIVE

CytomX Therapeutics (CTMX) experienced a surge in its stock price during the last trading session, accompanied by higher-than-average trading volume. However, the most recent changes in earnings estimates for the company do not indicate continued growth in the future.

Why Is CytomX (CTMX) Stock Up 180% Today?
InvestorPlace01 May 2024 Sentiment: POSITIVE

CytomX (NASDAQ: CTMX) shares are surging today following an announcement about the release date of its first quarter 2024 earnings report. The oncology-focused biopharmaceutical company informed investors that the report will be released after market close on May 8, 2024.

Why Is CytomX Therapeutics (CTMX) Stock Down 18% Today?
InvestorPlace12 March 2024 Sentiment: NEGATIVE

CytomX Therapeutics (NASDAQ: CTMX ) stock is falling hard on Tuesday after the clinical-stage, oncology-focused biopharmaceutical company released its latest earnings report. The CytomX Therapeutics earnings report notes that the company spent most of 2023 cutting costs to continue operations.

CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript
Seeking Alpha11 March 2024 Sentiment: POSITIVE

CytomX Therapeutics, Inc. (NASDAQ:CTMX ) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference Call Participants Joe Catanzaro - Piper Sandler Malcolm Kuno - JPMorgan Operator Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2023 Financial Results Conference Call.

CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
Zacks Investment Research11 March 2024 Sentiment: NEGATIVE

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.42 per share a year ago.

  • 1(current)

What type of business is CytomX Therapeutics?

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

What sector is CytomX Therapeutics in?

CytomX Therapeutics is in the Healthcare sector

What industry is CytomX Therapeutics in?

CytomX Therapeutics is in the Biotechnology industry

What country is CytomX Therapeutics from?

CytomX Therapeutics is headquartered in United States

When did CytomX Therapeutics go public?

CytomX Therapeutics initial public offering (IPO) was on 08 October 2015

What is CytomX Therapeutics website?

https://www.cytomx.com

Is CytomX Therapeutics in the S&P 500?

No, CytomX Therapeutics is not included in the S&P 500 index

Is CytomX Therapeutics in the NASDAQ 100?

No, CytomX Therapeutics is not included in the NASDAQ 100 index

Is CytomX Therapeutics in the Dow Jones?

No, CytomX Therapeutics is not included in the Dow Jones index

When was CytomX Therapeutics the previous earnings report?

No data

When does CytomX Therapeutics earnings report?

The next expected earnings date for CytomX Therapeutics is 07 November 2024